BGF - World Healthscience A2
Country/Region
Global
Sector
Gesundheit
Performance (1Y)
5.81%
Total expense ratio (TER)
1.81 %
Investment fund volume
12,041,072,013
Appropration of income
Accumulation
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE | 61.835 G | 0 Units |
| PRICE DETERMINATION TIME | 06/04/2026 / 09:56:15 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 61.835 | 59.26 |
| PREV. DAY'S PRICE | 60.53 | (06/03) |
| CHANGE DAY BEFORE | +1.30 | 2.16 % |
| 52 WEEK HIGH / LOW | 66.07 (11/26) | 54.07 (08/12) |
Master Data
| WKN | A0BL36 |
| ISIN | LU0171307068 |
| SYMBOL | ERDV |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Fund |
| MANAGEMENT TYPE | Active |
| INVESTMENT FUND TYPE | Equity Fund |
| PRODUCT DENOMINATION | BGF - World Healthscience A2 |
| MARKET MAKER | - |
| COUNTRY/REGION | Global |
| ISSUER/INVESTMENT COMPANY | BlackRock (Luxembourg) S.A. |
| MAPPED INDEX/BENCHMARK | MSCI World Health Care - Net TR |
| INDUSTRY | Gesundheit |
| FUND CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| DISTRIBUTION | Accumulation |
| TER | 1.81 % |
| LISTING DATE | 28/11/2008 |
| INVESTMENT FUND VOLUME | 12,041,072,013.40 |
| END OF FINANCIAL YEAR | 31/08/2026 |
| LICENSED FOR SALE IN GERMANY | Yes |
| TRADING HOURS | 07:30 - 22:00 |
| QUOTATION | continuous auction |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.43 % | 1.01 % | -6.48 % | -5.01 % | 5.81 % | 3.16 % | 22.88 % | -4.77 % |
| HIGH | 62.27 | 62.64 | 65.03 | 65.96 | 66.07 | 69.44 | 69.44 | 65.96 |
| LOW | 59.57 | 58.78 | 58.59 | 58.59 | 54.07 | 53.63 | 50.16 | 58.59 |
Investment strategy
Description
Der Fonds zielt auf maximalen Gesamtertrag ab, indem er weltweit mindestens 70% seines Gesamtvermoegens in Aktienwerte von Unternehmen anlegt, deren Geschaeftsaktivitaeten ueberwiegend in den Bereichen Gesundheit, Pharmazeutik und Medizintechnologie, der medizinischen Versorgung sowie in der Entwicklung der Biotechnologie liegen. Das Waehrungsrisiko wird flexibel gemanagt.